

# Technical Information Report

## AAMI TIR35: 2016/(R)2021

Sterilization of health care  
products—  
Radiation sterilization—  
Product adoption and  
alternative sampling  
plans for verification  
dose experiments and  
sterilization dose audits

Currently in preview, click buy full version

# Sterilization of health care products— Radiation sterilization— Product adoption and alternative sampling plans for verification dose experiments and sterilization dose audits

Approved 5 June 2016 and reaffirmed 6 October 2021 by  
AAMI

**Abstract:** Describes approaches to the selection and auditing of a sterilization dose that may reduce the number of product items required while maintaining assurance of attaining the desired sterility assurance level (SAL). This approach addresses sampling plans for verification dose experiments and sterilization dose audits. In addition the approaches to adopting a product into an established product family are defined.

**Keywords:** sterility, bioburden, radiation, health care products, dose, audits, product adoption, design verification, procedures

## AAMI Technical Information Report

A technical information report (TIR) is a publication of the Association for the Advancement of Medical Instrumentation (AAMI) Standards Board that addresses a particular aspect of medical technology.

Although the material presented in a TIR may need further evaluation by experts, releasing the information is valuable because the industry and the professions have an immediate need for it.

A TIR differs markedly from a standard or recommended practice, and readers should understand the differences between these documents.

Standards and recommended practices are subject to a formal process of committee approval, public review, and resolution of all comments. This process of consensus is supervised by the AAMI Standards Board and, in the case of American National Standards, by the American National Standards Institute.

A TIR is not subject to the same formal approval process as a standard. However, a TIR is approved for distribution by a technical committee and the AAMI Standards Board.

Another difference is that, although both standards and TIRs are periodically reviewed, a standard must be acted on—reaffirmed, revised, or withdrawn—and the action formally approved usually every five years, but at least every 10 years. For a TIR, AAMI consults with a technical committee about five years after the publication date (and periodically thereafter) for guidance on whether the document is still useful—that is, to check that the information is relevant or of historical value. If the information is not useful, the TIR is removed from circulation.

A TIR may be developed because it is more responsive to underlying safety or performance issues than a standard or recommended practice, or because achieving consensus is extremely difficult or unlikely. Unlike a standard, a TIR permits the inclusion of differing viewpoints on technical issues.

**CAUTION NOTICE:** This AAMI TIR may be revised or withdrawn at any time. Because it addresses a rapidly evolving field or technology, readers are cautioned to ensure that they have also considered information that may be more recent than this document.

All standards, recommended practices, technical information reports, and other types of technical documents developed by AAMI are *voluntary*, and their application is solely within the discretion and professional judgment of the user of the document. Occasionally, voluntary technical documents are adopted by government regulatory agencies or procurement authorities, in which case the adopting agency is responsible for enforcement of its rules and regulations.

Comments on this technical information report are invited and should be sent to AAMI, Attn: Standards Department, 901 N. Glebe Road, Suite 300, Arlington, VA 22203.

### *Published by*

Association for the Advancement of Medical Instrumentation  
901 N. Glebe Road, Suite 300  
Arlington, VA 22203

© 2016 by the Association for the Advancement of Medical Instrumentation

All Rights Reserved

Publication, reproduction, photocopying, storage, or transmission, electronically or otherwise, of all or any part of this document without the prior written permission of the Association for the Advancement of Medical Instrumentation is strictly prohibited by law. It is illegal under federal law (17 U.S.C. § 101, *et seq.*) to make copies of all or any part of this document (whether internally or externally) without the prior written permission of the Association for the Advancement of Medical Instrumentation. Violators risk legal action, including civil and criminal penalties, and damages of \$100,000 per offense. For permission regarding the use of all or any part of this document, visit the Copyright Clearance Center.

Printed in the United States of America

**ISBN 978-1-57020-618-4**

## Contents

Page

Glossary of equivalent standards .....	iv
Committee representation .....	v
Introduction .....	viii
1 Scope .....	1
2 Normative references .....	1
3 Terms and definitions .....	
4 Sample sizes for the verification dose experiment and dose establishment or dose audit .....	2
4.1 General .....	2
4.2 Selection and testing of product .....	3
4.3 Procedures for verification dose experiments and sterilization dose audits .....	3
4.3.1 General .....	3
4.3.2 Method 1: Alternative sampling plan for the verification dose experiment .....	3
5 Evaluation and Methods for Product Adoption .....	19
5.1 Evaluation of Candidate Product for Product Adoption .....	19
5.2 Methods of Product Adoption .....	20
5.3 Designation of the Candidate Product as the Product Family Representative .....	21
6 Maintenance of Product Families .....	21
Annex A (informative) Sample sizes for implementation of sampling plans and sampling scheme .....	23
Annex B (informative) Radiation product adoption assessment flow chart .....	24
Bibliography .....	26

## Tables

1 Method 1: Alternative sampling plan for the verification dose experiment .....	5
2 Alternative sampling plan 1 for the sterilization dose audit (Methods 1 or 2) .....	8
3 Alternative sampling plan 2 for the sterilization dose audit (Methods 1 or 2) .....	11
4 Alternative sampling plan 3 for the sterilization dose audit (Methods 1 or 2) .....	13
5 Alternative sampling scheme for Method 1: Sampling plan for the verification dose experiment (tightened inspection level) .....	10
6 Alternative sampling scheme for Method 1: Sampling plan for the sterilization dose audit (reduced inspection level) .....	19
A.1 Sample sizes for implementation of sampling plans and sampling scheme .....	23

## **Glossary of equivalent standards**

International Standards adopted in the United States may include normative references to other International Standards. AAMI maintains a current list of each International Standard that has been adopted by AAMI (and ANSI). Available on the AAMI website at the address below, this list gives the corresponding U.S. designation and level of equivalency to the International Standard.

[www.aami.org/standards/glossary.pdf](http://www.aami.org/standards/glossary.pdf)

Currently in preview, click buy full versi

## Committee representation

### Association for the Advancement of Medical Instrumentation Radiation Sterilization Working Group

This technical information report was developed and balloted by the AAMI Radiation Sterilization Working Group under the auspices of the AAMI Sterilization Standards Committee. Approval of this technical information report does not necessarily imply that all working group members voted for its approval.

At the time this document was published, the **AAMI Sterilization Standards Committee** had the following members:

*Cochair:* Mike Scholla, Dupont Protection Technologies

*Members:* Richard Bancroft, Steris Corporation  
Trabue Bryans, BryKor LLC  
Nancy Chobin, St Barnabas Healthcare System  
Phil Cogdill, Medtronic Inc Campus  
Ramona Conner, Association of Perioperative Registered Nurses  
Jackie Daley, Sinai Hospital of Baltimore Kim Darnell, CR Bard  
Gordon Ely, MiMedx Group  
Lisa Foster, Adiuvo Quality Sterilization Consulting  
Joel Gorski, NAMSA  
Joyce Hansen, Johnson & Johnson  
Doug Harbrecht, Sterility Assurance LLC  
Deborah Havlik, Hospira Worldwide Inc  
Sue Klacik, IAHCSSM  
Byron Lambert, Abbott Laboratories  
Colleen Landers, Timmins & District Hospital  
Michelle Luebke, Baxter Healthcare Corporation  
Jeff Martin, Alcon Laboratories Inc Patrick McCormick, Bausch & Lomb Inc  
Janet Prust, 3M Healthcare - Saint Paul, MN  
Nancy Rakiewicz, IUVO BioScience  
Andrew Sharavara, Propper Manufacturing Co Inc  
Mark Smith, Getinge USA  
Joan Spear, B Braun of America Inc  
Stacy Wiehle, Boston Scientific Corporation  
Sid Wiggs  
Martell Winters, Nelson Laboratories Inc  
Bill Young, Steris Inc International

*Alternates:* Suzanne Pottle, Boston Scientific Corporation  
Aaron Dement, Sterigenics International  
Dave Dick, Cardinal Health (MP&S)  
Ken Eddington, NAMSA  
Marianne Faivre-Swiat, Cardinal Health (MP&S) Danny Hutson, Becton Dickinson & Company  
Natalie Lind, IAHCSSM  
Jeffrey Marx, Steris Corporation  
Mary Mayo, CR Bard  
Gerry McDonnell, Johnson & Johnson  
David McGoldrick, Abbott Laboratories  
Jerry Nelson, Nelson Laboratories Inc  
Patrick Polito, IUVO BioScience  
Karen Polkinghorne, Dupont Protection Technologies  
Mike Sadowski, Baxter Healthcare Corporation  
Mike Schoene, Bausch & Lomb Inc  
Craig Wallace, 3M Healthcare

At the time this document was published, the **AAMI Radiation Sterilization Working Group** had the following members:

*Cochairs:* Emily Craven, Nordion Inc  
Pat Weixel, FDA/CDRH

*Members:* Ed Arcscott, NAMSA  
Simon Bogdansky, Allo Source  
Curt Bogue, Cook Inc  
Anne Booth, Booth Scientific Inc  
Riley Brown, St Jude Medical Inc  
Trabue Bryans, BryKor LLC  
Harry Bushar  
David Cardin, Zimmer Inc  
Sarah Chamberlain, Accuratus Labs Services  
Denise Cleghorn, Boston Scientific Corporation  
Gary Cranston, Consulting & Technical Services/PCS  
Greg Crego, IUVO BioScience  
Elaine Daniell, CR Bard  
Douglas Davie, Sterilization Validation Services  
Jeffrey DelGaudio, Medtronic Inc Campus  
Darci Diage, Direct Flow Medical Inc  
Dave Dion, Cardinal Health (MP&S)  
Francesco Famosi, Arthrex Inc  
William FitzGerald, FitzGerald & Associates Ltd  
Lisa Foster, Aduvo Quality & Sterilization Consulting  
Matthew Freeman, Terumo BCT  
Shelley Green, WuXi AppTec Inc  
Joyce Hansen, Johnson & Johnson  
Doug Harbrecht, Sterility Assurance LLC  
Deborah Havlik, Hospira Worldwide Inc  
Donna Horner, Abbott Laboratories  
Betty Howard, Steris Corporation  
Carolyn Kinsley, LexaMed Ltd  
Jeff Martin, Alcon Laboratories Inc  
Patrick McCormick, Bausch & Lomb Inc  
Nicole McLees, 3M Healthcare  
Rusty Mills, GE Healthcare  
Larry Nichols, Nutek Corporation  
Gerry O'Dell, Gerry O'Dell Consulting  
Kevin O'Hara, Sterigenics International  
Dave Parente, Ecolab  
Kimberly Patton, Nelson Dickinson & Company  
Michelle Peterson, Stryker Instruments Division  
Rudy Pina, Denatec Scientific Labs Inc  
Keith Renee, Terumo Americas Corporate  
Jody Robert, V.L. Gore & Associates Inc  
Manny Saez, Halyard Health  
Luza Salerno, Accuratus Labs Services  
Harry Shaffer, Sterilization Consulting Services  
Michael Sprague, Ethide Laboratories Inc  
Sopheak Srun, Quality Tech Services Inc  
Fenil Sutaria, Medline Industries Inc  
Jill Warren, WuXi AppTec Inc  
Bud Weisman, Fresenius Medical Care  
Beverly Whitaker, Indigo Consulting Group LLC  
Martell Winters, Nelson Laboratories Inc

*Alternates:* MarJean Boyter, Fresenius Medical Care -  
Carolyn Braithwaite-Nelson, Spectranetics Corporation  
Rachel Brewer, IUVO BioScience  
Claudia Camp, Stryker Instruments Division

Jessica Desmond, Accuratus Labs Services  
Brian Drumheller, CR Bard  
Diane Faivre-Swiat, Cardinal Health (MP&S)  
Niki Fidopiastis, Sterigenics International  
Scott Giraud, Medtronic Inc Campus  
Mike Graybill, 3M Healthcare  
Henry Hart, Zimmer Inc  
Fatima Hasanain, Nordion Inc  
Brent Huberty, Boston Scientific Corporation  
Nichole Jackson, Ecolab  
Chris Johnson, Steris Corporation  
Satu King, Spectranetics Corporation  
Chris Kobus, GE Healthcare  
Ezra Koski, Terumo BCT  
Vu Le, Abbott Laboratories  
Antonio Lopez-Feliciano, Becton Dickinson & Company  
Bradley Lundahl, Johnson & Johnson  
Connie McChesney, Alcon Laboratories Inc  
Joseph Mello, Ethide Laboratories Inc  
Ken Paddock, Baxter Healthcare Corporation  
Dupeh Palmer-Ochieng, FDA/CDRH  
Michelle Pierce, NAMSA  
Nancy Rakiewicz, IUVO BioScience  
Robert Reich, LexaMed Ltd  
Reginald Roberts, Medline Industries Inc  
Jade Schiesser, Quality Tech Services Inc  
Mike Schoene, Bausch & Lomb Inc  
Mara Tafoya, WuXi AppTec Inc  
Kristen Thompson, Stryker Instruments Division  
Wendy Wangsgard, Nelson Laboratories Inc  
Keisha Weaver, Halyard Health  
Cas Woss, FitzGerald & Associates Ltd

---

NOTE—Participation by federal agency representatives in the development of this technical information report does not constitute endorsement by the federal government or any of its agencies.

---

## Introduction

This technical information report (TIR) is intended to be used in conjunction with the ANSI/AAMI/ISO 11137 series. One of the activities encompassed within this series is the selection and routine auditing of the sterilization dose to be applied to health care products, and, in relation, the number of product items to be used to assure the sterility assurance level (SAL) is attained. A primary manufacturer might wish to reduce this number.

The guidance contained within this TIR provides strategies by which the primary manufacturer may reduce the total number of product items to be tested for establishing and maintaining the sterilization dose with alternative sampling plans. The approach to alternative sampling plans given in this TIR employs alternative sampling plans that are statistically equivalent to the sample size of 100 product items as described in Methods 1 and 2 of ANSI/AAMI/ISO 11137-2, even though a different number of products is tested. However, if there is a dose audit failure when using this approach, there is no provision for the augmentation of the sterilization dose. In this situation, the dose must be re-established or another validation method utilized.

The TIR also provides guidance by which the primary manufacturer may adopt new products or re-designed products into an established product family with a technical evaluation. Based upon the technical evaluation the method to be used to adopt the product into the family can be determined.

Text of this document was adapted from ANSI/AAMI/ISO 15843:2000. This document, along with the ANSI/AAMI/ISO 11137 series, supersedes ANSI/AAMI/ISO 15843:2000.

---

NOTE—This technical information report is not a standard and the material contained herein is not normative in nature. The committee has in a few places used the term "shall" based on their knowledge of requirements contained in relevant standards and/or regulatory requirements.

---

# Sterilization of health care products—Radiation sterilization—Product adoption and alternative sampling plans for verification dose experiments and sterilization dose audits.

## 1 Scope

This TIR describes approaches to the selection and auditing of a sterilization dose that may reduce the number of product items required while maintaining assurance of attaining the desired sterility assurance level (SAL). This approach addresses sampling plans for verification dose experiments and sterilization dose audits. Additionally, guidance for adopting a product into an existing product family and maintenance of product families is provided.

## 2 Normative references

*ANSI/AAMI/ISO 11137-1:2006/(R) 2010 & A1:2013 Sterilization of health care products – Radiation – Part 1: Requirements for the development, validation and routine control of a sterilization process for medical devices*

*ANSI/AAMI/ISO 11137-2:2013 Sterilization of health care products – Radiation – Part 2: Establishing the sterilization dose*

*ANSI/AAMI/ISO 11737-1:2006/(R) 2011 Sterilization of health care product – Microbiological methods – Part 1: Determination of the population of microorganisms on product*

*ANSI/AAMI/ISO 11737-2:2009/(R) 2012 Sterilization of health care product – Microbiological methods – Part 2: Tests of sterility performed in the definition, validation and maintenance of a sterilization process*

## 3 Terms and definitions

For the purposes of this TIR, the following terms and definitions apply:

### 3.1 augmentation

Action taken to increase the sterilization dose based upon the results obtained from a sterilization dose audit.

### 3.2 bioburden

Population of viable microorganisms on or in product and/or a sterile barrier system.

[ANSI/AAMI/ISO TIR11139:2006]

### 3.3 candidate product

The product being examined for adoption into an existing product family.

### 3.4 false positive

Test result interpreted as growth arising from the product, or portions thereof, tested when either growth resulted from extraneous microbial contamination or turbidity occurred from interaction between the product, or portions thereof, and the test medium.

[ANSI/AAMI/ISO 11137-2:2013]

### 3.5 health care product

Medical device(s), including *in vitro* diagnostic medical device(s), or medical product(s), including biopharmaceuticals.

[ANSI/AAMI/ISO TIR11139:2006]